Insulet Co. (NASDAQ:PODD) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 33.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,371 shares of the medical instruments supplier’s stock after acquiring an additional 11,210 shares during the period. Natixis Advisors LLC owned 0.06% of Insulet worth $11,584,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in Insulet during the fourth quarter worth approximately $36,000. SRS Capital Advisors Inc. raised its position in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 56 shares during the period. Friedenthal Financial acquired a new position in Insulet in the fourth quarter valued at $57,000. TD Private Client Wealth LLC grew its position in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 56 shares during the period. Finally, Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PODD. StockNews.com cut shares of Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Canaccord Genuity Group upped their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective on the stock. Piper Sandler raised their target price on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, TD Cowen lifted their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.47% of the stock is owned by insiders.

Insulet Stock Up 2.1 %

Shares of NASDAQ:PODD opened at $265.82 on Thursday. The company’s fifty day moving average is $272.21 and its two-hundred day moving average is $256.19. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The stock has a market capitalization of $18.67 billion, a price-to-earnings ratio of 45.91, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.